These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8808454)

  • 1. Erythropoietin can be administered during dialysis. A kinetic analysis.
    Petersen J; Kang MS; Hays MT
    ASAIO J; 1996; 42(1):27-33. PubMed ID: 8808454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 3. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin.
    Bárány P; Pettersson E; Ahlberg M; Hultman E; Bergström J
    Clin Nephrol; 1991 Jun; 35(6):270-9. PubMed ID: 1873941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
    Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M; Miyazono K; Urabe A; Takaku F
    Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
    Cuero CJ; Pérez Guardia E; de Rivera C
    Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin. A new frontier.
    Rutherford C
    J Intraven Nurs; 1991; 14(3):163-5. PubMed ID: 2033478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of correcting anemia with recombinant erythropoietin on the central hemodynamic indices of patients on regular hemodialysis].
    Ermolenko VM; Khvoĭnitskiĭ VA; Suprun EK; Tsukerman LI; Pokrovskiĭ IuA
    Ter Arkh; 1992; 64(7):86-8. PubMed ID: 1440377
    [No Abstract]   [Full Text] [Related]  

  • 14. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis: a prospective cohort study from the J-DOPPS II study.
    Yokoyama H; Kawaguchi T; Wada T; Takahashi Y; Higashi T; Yamazaki S; Fukuhara S; Akiba T; Akizawa T; Asano Y; Kurokawa K; Saito A;
    Nephron Clin Pract; 2008; 109(2):c100-8. PubMed ID: 18596379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kukhtevich AV
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.